Ad

VNRX – VolitionRX Ltd

Compliant

★★★☆☆

VolitionRX Ltd is Shariah compliant. The company’s financials pass three standards and fail in two.

$145,386,827

Market cap

14.92%

Revenue Growth

BUY

Analysts' Rating

Ad

Recommendation Rating

2

1

2

3

4

5

1 = STRONG BUY | 2 = BUY | 3 = HOLD | 4 = UNDERPERFORM | 5 = SELL

Analysts’ Price Targets

Mean 7.6

Low: 6

High: 9

Total Analysts: 5

Company Profile

VolitionRx Limited is a multi-national epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop blood tests to help diagnose and monitor a range of diseases, including certain cancers and diseases associated with NETosis, such as sepsis and COVID-19. The Company’s tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluids. Its Nucleosomics technology uses chromosomal structures called nucleosomes as biomarkers in cancer and other diseases. Its key pillars include Nu.Q , Nu.Q NETs, Nu.Q Capture, Nu.Q Discover and Nu.Q Vet. Its Nu.Q family of tests acts as an early warning system by monitoring treatment response, disease progression and remission. Its Nu.Q tests use epigenetic information from tumor cells nucleosomes that helps physicians select the treatment for each patient, monitor their response and disease progression.

We do our best to screen stocks as accurately as possible. Please let us know in the comments if you spot an error or find something questionable. Jazaak Allahu khairan

Ad

Responses